Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma

被引：0
|
作者：
P Kapoor
S Kumar
S J Mandrekar
K M Laumann
A Dispenzieri
M Q Lacy
D Dingli
M A Gertz
R A Kyle
P R Greipp
S V Rajkumar
T E Witzig
机构：
[1] Mayo Clinic,Division of Hematology
[2] Mayo Clinic,Division of Biomedical Statistics and Informatics
来源：
Leukemia | 2011年 / 25卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1195 / 1197
页数：2
相关论文
共 50 条
  • [41] Thromboembolic Events (TEE) with Lenalidomide-Based Therapies for Multiple Myeloma (MM): Emory Experience.
    Nooka, Ajay K.
    Kaufman, Jonathan L.
    Heffner, Leonard T.
    Gleason, Charise L.
    Lonial, Sagar
    [J]. BLOOD, 2009, 114 (22) : 1496 - 1496
  • [42] Comparing the Efficacy of Aspirin or Low Molecular Weight Heparin or Vitamin K Antagonists in the Risk of Thromboembolic Events in Patients with Multiple Myeloma Treated with Lenalidomide-Based Therapy
    Louzada, Martha L.
    Mateos, Maria-Victoria
    Siqueira, Lenicio
    Bermejo, Jose-Maria B.
    Ocio, Enrique M.
    Porras, Jose-Ramon
    [J]. BLOOD, 2015, 126 (23)
  • [43] Lenalidomide-based response-adapted therapy for older adults without high risk myeloma
    Baz, Rachid
    Mahrukh, Syeda
    Naqvi, Hussnain
    Lee, Jae-Hoon
    Brayer, Jason
    Hillgruber, Nancy
    Fridley, Brooke L.
    Shain, Kenneth H.
    Sullivan, Daniel M.
    Alsina, Melissa
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (05) : 735 - 743
  • [44] Activity with Thalidomide-Based Therapy Following Lenalidomide Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Young, Trieu
    Chu, Chia-Min
    Xu, Wei
    Anglin, Peter
    Trudel, Suzanne
    Reece, Donna E.
    Chen, Christine
    Kukreti, Vishal
    [J]. BLOOD, 2009, 114 (22) : 1483 - 1483
  • [45] Treatment of multiple myeloma with immunomodulatory drugs - thalidomide, lenalidomide and pomalidomide
    Rzepecki, Piotr
    [J]. WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2009, 13 (05): : 265 - 275
  • [46] Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma
    Laubach, Jacob P.
    Schlossman, Robert L.
    Mitsiades, Constantine S.
    Anderson, Kenneth C.
    Richardson, Paul G.
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2011, 4 (01) : 51 - 60
  • [47] Lenalidomide and thalidomide: An evolving paradigm for the management of multiple myeloma - Introduction
    Anderson, KC
    Prince, HM
    [J]. SEMINARS IN HEMATOLOGY, 2005, 42 (04) : S1 - S2
  • [48] THE EFFICACY OF COMBINATION THERAPY WITH LENALIDOMIDE AND DEXAMETHASONE IN THE TREATMENT OF RELAPSED MULTIPLE MYELOMA
    Szudy-Szczyrek, Aneta
    Legiec, Wojciech
    Manko, Joanna
    Gmyz, Katarzyna
    Szczyrek, Michal
    Hus, Marek
    [J]. HEALTH PROBLEMS OF CIVILIZATION, 2015, 9 (02) : 50 - 54
  • [49] Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment
    Matsue, Kosei
    Sunami, Kazutaka
    Matsumoto, Morio
    Kuroda, Junya
    Sugiura, Isamu
    Iwasaki, Hiromi
    Chung, Weiyuan
    Kuwayama, Shigeki
    Nishio, Mitsufumi
    Lee, Kim
    Iida, Shinsuke
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 116 (01) : 122 - 130
  • [50] Effect of Immediate Prior-Line Lenalidomide or Thalidomide Therapy on Response To Pomalidomide In Multiple Myeloma
    Hwa, Yi Lisa
    Laumann, Kristina M.
    LaPlant, Betsy R.
    Buadi, Francis
    Dingli, David
    Dispenzieri, Angela
    Gertz, Morie A.
    Go, Ronald S.
    Hayman, Suzanne R.
    Kapoor, Prashant
    Kumar, Shaji K.
    Leung, Nelson
    Lin, Yi
    Lust, John A.
    McCurdy, Arleigh
    Mikhael, Joseph
    Roy, Vivek
    Russell, Stephen
    Zeldenrust, Steven R.
    Rajkumar, S. Vincent
    Lacy, Martha Q.
    [J]. BLOOD, 2013, 122 (21)
12345